Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues?
Combining atezolizumab 1200 mg with bevacizumab 15 mg/kg: based on science or just revenues? Eur J Cancer. 2023 Sep 20; 194:113349.
PMID: 37806256
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs? JAMA Oncol. 2023 Aug 31.
PMID: 37651126
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies.
Interventional pharmacoeconomics for immune checkpoint inhibitors through alternative dosing strategies. Br J Cancer. 2023 10; 129(9):1389-1396.
PMID: 37542109
Alternative Trastuzumab Dosing Schedules Are Associated With Reductions in Health Care Greenhouse Gas Emissions.
Alternative Trastuzumab Dosing Schedules Are Associated With Reductions in Health Care Greenhouse Gas Emissions. JCO Oncol Pract. 2023 09; 19(9):799-807.
PMID: 37450776
Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy.
Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy. Ann Oncol. 2023 08; 34(8):638-644.
PMID: 37230253
US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?
US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action? J Clin Oncol. 2023 05 10; 41(14):2488-2492.
PMID: 36780590
In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation.
In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation. J Clin Pharmacol. 2023 06; 63(6):672-680.
PMID: 36624662
Implementation of pharmacogenomics into inpatient general medicine.
Implementation of pharmacogenomics into inpatient general medicine. Pharmacogenet Genomics. 2023 02 01; 33(2):19-23.
PMID: 36729768
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022. Ann Oncol. 2023 01; 34(1):48-60.
PMID: 36182023
The dosing of ibrutinib and related Bruton's tyrosine kinase inhibitors: eliminating the use of brute force.
The dosing of ibrutinib and related Bruton's tyrosine kinase inhibitors: eliminating the use of brute force. Blood Adv. 2022 09 13; 6(17):5041-5044.
PMID: 35816636